Genentech, Inc.
NEWS
It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Bristol-Myers Squibb has appointed Christopher Boerner to replace Murdo Gordon, who left the company on August 3. Boerner will take on the positions of executive vice president and chief commercial officer, effective immediately.
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
Heidelberg, Germany-based Affimed NV inked a licensing deal with Switzerland-based Roche for $96 million upfront, but that was only a fraction of the entire deal. Affimed shares rocketed, more than doubling to hit $148.07.
Roche has been hit with another departing executive. This morning the Swiss pharma giant announced that Roland Diggelmann, the chief executive officer of the company’s diagnostics division, is leaving at the end of September.
Genentech is slashing 223 jobs at its South San Francisco headquarters, according to a Worker Adjustment and Retraining Notification posted on a California state government website. The layoffs will go into effect on Aug. 31, according to the WARN posting.
JOBS
IN THE PRESS